From: Mutation profile of non-small cell lung cancer revealed by next generation sequencing
Gene | Alteration | Targeted therapy | Frequency |
---|---|---|---|
Any gene (s) | Â | Â | 34 |
EGFR | L858R + E709G | Gefitinib | 1 |
 | Exon 19 deletion | Erlotinib, Gefitinib, Afatinib | 12 |
 | L858R + T790M | Osimertinib | 1 |
 | L858R | Erlotinib, Gefitinib, Afatinib | 12 |
KRAS | G12V | Resistance to Erlotinib and Gefitinib | 1 |
 | G12A | Resistance to Erlotinib and Gefitinib | 1 |
 | G12D | Resistance to Erlotinib and Gefitinib | 1 |
 | Q61H | Resistance to Erlotinib and Gefitinib | 1 |
ERBB2 | Insertion | Afatinib, Dacomitinib, Trastuzumab | 2 |
MET | R1004X | Crizotinib | 1 |
 | c.1738 + 1G > T |  |  |
NTRK1 | R646C | Entrectinib | 1 |